LONDON -- August 22, 2014 -- Women treated for the cancer Hodgkin lymphoma will be able to better understand their risks of future infertility after researchers estimated their risk of premature menopause with different treatments.
The findings, published in the Journal of the National Cancer Institute, are based on the experience of more than 2,000 young women in England and Wales treated for Hodgkin lymphoma over a period of more than 40 years.
Previous research has suggested that women with Hodgkin lymphoma who receive certain types of chemotherapy or radiotherapy are at increased risk of going through the menopause early, but there was insufficient information to provide patients with detailed advice.
The current study provides precise estimates of risk for women depending on which treatment types and doses they received and at what age, allowing doctors to give them detailed advice about their risks of future infertility.
For the study, Anthony Swerdlow, MD, Institute of Cancer Research, London, United Kingdom, and colleagues followed-up 2,127 women who had been treated for Hodgkin lymphoma in England and Wales between 1960 and 2004, and who had been aged younger than 36 years at the time. All had received treatment with chest radiotherapy, sometimes alongside other treatments.
Of the women, 605 underwent non-surgical menopause before the age of 40. This was a large enough number for the researchers to estimate accurate risks of menopause at different ages depending on the mixture and doses of treatments they received and the age they received them.
The researchers produced a risk table which could help improve the advice that clinicians are able to give to women who have undergone treatment for the disease. Several of the treatments caused a sharp increase in premature menopause risk.
For example, a woman who had received 6 or more cycles of a standard chemotherapy regimen in her late 20s, but without receiving radiotherapy to the pelvic area, had around a 18% chance of undergoing menopause by the age of 30, or a 58% chance by age 40.
Overall, risk of premature menopause was more than 20-fold raised after ovarian radiotherapy, and also after some specific chemotherapy regimens. Risk of menopause by age 40 was 81% after receiving ovarian radiotherapy at an overall dose of 5 or more Grays, and up to 75% after chemotherapy, depending on the type, although only 1% after receiving ABVD.
“Hodgkin lymphoma often affects younger women, and although fortunately most survive the disease, treatments including certain types of chemotherapy and pelvic radiotherapy can lead to premature menopause,” said Dr. Swerdlow.
“We hope our study will help women to understand better, in consultation with their doctors, their risks of future infertility following treatment for this malignancy,” he added. “By looking in a much larger group of women than previous studies of this type, we were able to produce age and treatment specific risk estimates that we hope will be of practical use to individual women.”
SOURCE: Institute of Cancer Research
DG News lets you be the first to know advances in medical research, results from conferences, and changes in healthcare policy and business.